Short answer
Celcuity Inc. (CELC) filed its Q1 2026 10-Q quarterly report on May 14, 2026 for the quarter ended Mar 31, 2026.
Q1 2026 key financials · XBRL
- Net income
- −$53M
- −42.8% YoY
- EPS (diluted)
- −$0.97
- −12.8% YoY
Source: XBRL data from the Celcuity Inc. (CELC) Q1 2026 10-Q on SEC EDGAR. USD.
Celcuity Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- VIKTORIA-1 Study 2 topline results: gedatolisib triplet PFS statistically superior to alpelisib plus fulvestrant
- VIKTORIA-2 redesign: approximately 440 and 740 patients, with topline data expected by end of 2028 and in 2030
- FDA accepted WT-cohort NDA; Priority Review PDUFA goal date July 17, 2026
Risk Factors
- No material changes to risk factors disclosed in the 2025 10-K
- Unknown or currently immaterial risks could adversely affect business, financial condition, or operating results
- No newly triggered regulatory, legal, compliance, operational, competitive, market, or financial risks identified
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Celcuity Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.